We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
The meeting of the Advisory Committee on Vaccines (ACV).
The committee provided advice on two applications:
- Major variation (booster dose for individuals aged 12-15 years old) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Comirnaty; active ingredient Tozinameran; sponsor Pfizer Australia Pty Ltd) that had been under evaluation from March 2022
- Major variation (booster dose for individuals aged 18 years and over) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Nuvaxovid; active ingredient SARS-CoV-2 rS with Matrix-M adjuvant; sponsor Biocelect Pty Ltd) that had been under evaluation from March 2022.
Members
Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.